Symphogen
Daniel Andersen's work experience began in 2006 when they worked as a student employee at FL Smidth until 2008. From 2008 to 2011, they worked at CMC Biologics A/S as a GMP surveillance employee. In 2011, they joined the Centre for Medical Parasitology, University of Copenhagen as a Research Assistant, where they focused on testing the ability of P. falciparum isolates to bind CSA and investigating the molecular basis for variations in CSA binding capacity. Daniel then pursued a PhD at DTU Bioengineering from 2012 to 2017, followed by a postdoc position from 2017 to 2021 at the same institution. Currently, they are working as a Scientist at Symphogen, starting in 2021.
Daniel Andersen attended Borupgaard Amtsgymnasium from 2001 to 2004, where they obtained their Stx degree in Mathematical. Following this, they pursued higher education at Københavns Universitet - University of Copenhagen from 2005 to 2011. During this time, they obtained their Cand.scient.molbiomed degree in Molecular Biomedicine.
Symphogen
3 followers
Symphogen is a clinical-stage antibody oncology focused company with a differentiated product pipeline and significant commercial opportunities. Inspired by nature, led by science and driven by people, we passionately strive to make that discovery that may have great effect on the lives of patients, their families, and their caregivers. Based on our monoclonal antibody (mAb) research platform, we create differentiated mAb and mAb mixture products candidates. Our pre-clinical and clinical pipeline is well suited for a precision-medicine approach by addressing well-defined, biomarker-selected patient populations. We are headquartered in Denmark with operations in the US.